In:
Journal of the European Academy of Dermatology and Venereology, Wiley, Vol. 32, No. 7 ( 2018-07), p. 1164-1172
Abstract:
Identification of myositis‐specific autoantibodies ( MSA s) for dermatomyositis ( DM ) could allow the characterization of an antibody‐associated clinical phenotype. Objective We sought to define the clinical phenotype of DM and the risk of cancer, interstitial lung disease ( ILD ) and calcinosis based on MSA . Methods A 3.5‐year multicentre prospective study of adult DM patients was conducted to determine the clinical phenotype associated with MSA s and the presence of cancer, ILD and calcinosis. Results MSA s were detected in 47.1% of 117 included patients. Patients with antimelanoma differentiation‐associated protein‐5 antibodies (13.7%) had significantly more palmar violaceous macules/papules [odds ratio ( OR ) 9.9], mechanic's hands ( OR 8), cutaneous necrosis ( OR 3.2), articular involvement ( OR 15.2) and a higher risk of ILD ( OR 25.3). Patients with antitranscriptional intermediary factor‐1 antibodies (11.1%), antinuclear matrix protein‐2 antibodies (6.8%) and antiaminoacyl‐transfer RNA synthetase (5.1%) had, respectively, significantly more poikiloderma ( OR 5.9), calcinosis ( OR 9.8) and articular involvement ( OR 15.2). Cutaneous necrosis was the only clinical manifestation significantly associated with cancer ( OR 3.1). Conclusion Recognition of the adult DM phenotype associated with MSA s would allow more accurate appraisal of the risk of cancer, ILD and calcinosis.
Type of Medium:
Online Resource
ISSN:
0926-9959
,
1468-3083
DOI:
10.1111/jdv.2018.32.issue-7
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2022088-1
Permalink